Rocket Pharmaceuticals Inc. Common Stock (RCKT)
Stock · NASDAQ · Health Care
$2.18as of 10/16/2026
Price chart
Active signals
Resistance level
$3.54
Industry
Biotechnology: Pharmaceutical Preparations
RCKT Signal Track Record
How signals performed across all stocks →What RCKT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -2.4% | 41% | September 10, 2026 |
| Bollinger Band Breakdown | 21 | -3.4% | 43% | September 23, 2026 |
| Bollinger Band Breakout | 21 | -2.1% | 43% | August 28, 2026 |
| 200-Day Moving Average TouchActive now | 18 | -2.5% | 39% | August 24, 2026 |
| Any 20-session window (baseline) | -2.1% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 202
- Website
- www.rocketpharma.com/
Fundamentals
- 1-day range
- $2.26$2.55
- Market cap
- $386.55M
- P/E (trailing)
- —
- P/E (forward)
- -1.77
- EPS (trailing)
- $-0.18
- Dividend yield
- —
- Beta
- 0.48
- Avg. volume
- 1.70M
- Dividend pay date
- January 5, 2018
52-week range
$2.42$5.45
Next earnings: November 5, 2026 · EPS estimate $-0.41
Forecasts
12 analyst ratings
Buy 55%
Hold 35%
Sell 10%
1-year price forecast
High
$15
+588.1%
Median
$9.5
+335.8%
Low
$2.95
+35.3%
Rocket Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RCKTRocket Pharmaceuticals Inc. Common Stock$2.18▼ 7.63%Market cap $386.55MP/E —$2.42$5.45
- ENTAEnanta Pharmaceuticals Inc. Common Stock$11.1▼ 3.23%Market cap $387.91MP/E —$10.2$17.15
- ABEOAbeona Therapeutics Inc. Common Stock$4.43▼ 4.73%Market cap $393.27MP/E 5.50$4$7.65
- UPBUpstream Bio Inc. Common Stock$2.76▼ 18.10%Market cap $373.87MP/E —$3.29$33.68
- AVIRAtea Pharmaceuticals Inc. Common Stock$4.32▼ 4.64%Market cap $399.34MP/E —$2.87$6.45
- PRLDPrelude Therapeutics Incorporated Common Stock$3.26▼ 1.81%Market cap $372.74MP/E —$1.16$6.83
- DMACDiaMedica Therapeutics Inc. Common Stock$7.57▼ 5.85%Market cap $364.79MP/E —$5.25$10.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals Inc. Common Stock | $386.55M | — | $2.18 | ▼ 7.63% | $2.42$5.45 |
| ENTA Enanta Pharmaceuticals Inc. Common Stock | $387.91M | — | $11.1 | ▼ 3.23% | $10.2$17.15 |
| ABEO Abeona Therapeutics Inc. Common Stock | $393.27M | 5.50 | $4.43 | ▼ 4.73% | $4$7.65 |
| UPB Upstream Bio Inc. Common Stock | $373.87M | — | $2.76 | ▼ 18.10% | $3.29$33.68 |
| AVIR Atea Pharmaceuticals Inc. Common Stock | $399.34M | — | $4.32 | ▼ 4.64% | $2.87$6.45 |
| PRLD Prelude Therapeutics Incorporated Common Stock | $372.74M | — | $3.26 | ▼ 1.81% | $1.16$6.83 |
| DMAC DiaMedica Therapeutics Inc. Common Stock | $364.79M | — | $7.57 | ▼ 5.85% | $5.25$10.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For ThursdayBenzinga · 10/8/2026
- Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4Benzinga · 10/8/2026
- Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facilityYahoo · 10/7/2026
- Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor WebinarYahoo · 10/7/2026
- Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4Benzinga · 10/7/2026
- MARKETS LIVE: US futures slide ahead of Fed minutes as bond yields and oil riseYahoo · 10/7/2026
- Rocket receives $150m credit facility to advance cardiovascular portfolioYahoo · 10/7/2026
- Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified ProtocolBenzinga · 10/7/2026
Insider Activity
Insider Actions →Acquired
565.0K
Disposed
126.0K
- Martin Wilson · September 11, 2026 · Sale75.4K @ $3.4
- Martin Wilson · August 18, 2026 · Sale631 @ $3.38
- Gaurav Shah · August 18, 2026 · Sale2.3K @ $3.38
- Gaurav Shah · August 13, 2026 · Sale2.8K @ $3.38
- Martin Wilson · August 13, 2026 · Sale3.5K @ $3.38
- Christopher James Stevens · August 11, 2026 · Sale36.7K @ $3.5
- Sarbani Chaudhuri · August 11, 2026 · Sale4.7K @ $3.5
- Christopher James Stevens · August 3, 2026 · Grant101.4K
- Christopher James Stevens · August 3, 2026 · Grant73.3K
- David P. Southwell · August 3, 2026 · J150.0K
- Peter Fong · June 18, 2026 · Grant64.9K
- David P. Southwell · June 18, 2026 · Grant64.9K
- David P. Southwell · June 18, 2026 · Grant22.9K
- Peter Fong · June 18, 2026 · Grant22.9K
- Mikael Dolsten · June 18, 2026 · Grant64.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 91.44M
- Total value held
- $323.77M
- Institutional holders
- 192
Top holders this quarter
- Unknown17.69M
- Unknown7.83M
- Unknown5.11M
- Unknown4.49M
- Unknown3.78M
- Unknown3.57M
- Unknown3.17M
- Unknown3.13M
- Unknown3.12M
- Unknown3.07M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial
Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.